Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Planned for Oct 16, 2026 · Notice filed Oct 16, 2026
An Ionis Pharmaceuticals officer told the SEC about a plan to sell $60K of Ionis Pharmaceuticals shares around Oct 16, 2026. The filing says the shares were acquired as compensation.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
None found in footnotes
Only flagged when a footnote says so; never inferred
Insider buying
First insider buy since May 2025Traded Nov 10 · filed 3 days later
An Ionis Pharmaceuticals director paid $148K out of pocket for Ionis Pharmaceuticals shares. It was the first purchase in 18 months. Shares held went up 23% with this purchase.
Fund moves
From a 13F filed Nov 13, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Insider filing
Traded Oct 15 · filed 5 days later
Derivative exercise or conversion — not an open-market buy.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.